Last update April 15, 2024

C08CA02

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is a dihydropyridine-type calcium channel blocker. It is used in the treatment of hypertension and angina pectoris. Oral administration once daily.

At latest update no published data were found on excretion into breast milk.

Its high percentage of plasmatic protein binding and very wide volume of distribution makes it highly unlikely a passage into breast milk.

Its very low oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk, except in the premature and in the immediate neonatal period in which there may be greater intestinal permeability.

Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.

It has been described an increased Prolactin plasma level and gynecomastia after using felodipine and cyclosporine. (Pan 1997)

Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C08CA02 is Felodipine in ATC Code/s.

Is written in other languages:

Tradenames

Main tradenames from several countries containing C08CA02 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 10 - 25 %
Molecular weight 384 daltons
Protein Binding 99 %
VD 10 l/Kg
Tmax 3 - 5 hours
11 - 25 hours

References

  1. AEMPS. Felodipino. Ficha técncia. 2015 Full text (in our servers)
  2. Felodipine. Product Monograph. Sanofi-Aventis 2006 Full text (in our servers)
  3. Pan Y, Grindstaff A, Cassada D, Goldman M, Taylor J. Bilateral reduction mammoplasty in a patient treated with calcium channel blocker and cyclosporine after renal transplant: a case report. Transplantation. 1997 Abstract

Total visits

609

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM